not facilitated as compared with mature quiescent skeletal muscle. 6, 7 The pathologic changes affecting dystrophic muscle are of considerable importance to gene therapy for muscular dystrophy. Most dystrophic muscles, particularly in the early stages of the disease, are characterized by the coexistence of myofibers at different stages of maturity. Repeated cycles of necrosis and regeneration attempts result in a predominance of immature young regenerative myofibers. A suitable gene delivery system should allow gene transfer into myofibers at various stages of maturity in order to provide efficient and durable correction of the disease.
In the present study, gene transfer experiments were performed in both normal and regenerating rat skeletal muscles to determine whether rAAV-mediated gene transfer is efficient in regenerating muscle tissue. An experimental model of muscle injury, associated with a remarkably reproducible chronology of necrosis and subsequent regeneration, was used to allow more precise study of the most relevant factors involved in the efficiency of gene transfer into pathologic muscle tissue.
Eight-week-old adult female Wistar rats (200-250 g) were used in all experimental procedures. At least five animals were involved in each set of experiments. Muscle necrosis was induced by notexin administered as a single injection into the left tibialis anterior (TA) muscle. Contralateral TA muscle, injected with the same volume of saline, served as the healthy control. The chronology of notexin-induced injury and subsequent regeneration was remarkably reproducible (Figure 1 ). To assess transduction efficiency at different times of the regenerative process, viral solutions were injected into regenerating and contralateral muscles 3 days (satellite cell proliferation period) or 5 days (myotube growth period) after notexin treatment. An rAAV encoding a ␤-galactosidase with a nuclear-targeted localization signal, under the control of the cytomegalovirus immediate-early promoter, was used (rAAV CMV nls LacZ). Viral solutions were prepared and purified, as previously described. 8, 9 rAAV titer and level of contaminating adenovirus and rep-positive AAV were measured by dot-blot analysis and modified replication center assay. The rAAV solutions used in the present study were free of detectable infectious adenovirus and wild-type rep-positive AAV. The level of transgene expression was quantified by counting the number of myofibers expressing transgene product in the muscle sample and by Southern blot analysis. In vivo rAAV gene transfer in regenerating rat skeletal muscles led to high levels of transgene expression when vector injection was performed 5 days after necrosis induction ( Figure 2 ). In our experiments, the highest transduction level was obtained in a regenerating sample, reaching 2230 myofibers 2 months after vector injection (mean ± standard error for the regenerating group at 2 months: 1235 ± 350 transduced myofibers). This level of rAAVmediated transduction is one of the highest reached in reported experiments dealing with muscle tissue in animal models larger than mice. 10 Gene transfer in post-necrotic myofibers was demonstrated on histological sections by the presence of numerous centrally localized nuclei showing ␤-gal activity in regenerating muscle samples (Figure 3) . Southern blot analyses of transduced tissue indicated that improvement in gene transfer efficiency during regeneration was associated with an increase in the number of viral genomic copies found in transduced muscle (Figure 4) .
Conversely, vector injection during the early regenerative process (ie 3 days after necrosis induction) led to a decrease in the gene transfer efficiency of rAAV-based vectors (Figure 2 ), which is in agreement with previous reports of rAAV-mediated gene transfer experiments performed during the immediate or early part of the regenerative process (ie 1 to 3 days after myotoxic injury). 6, 7 However, the proliferation of activated satellite cells at 
Figure 4 Evaluation of the efficiency of rAAV-mediated gene transfer by Southern blot analysis of muscle DNA genomes. Southern blot analyses were performed on representative muscle extracts from two animals of the 5 days post-necrosis injection group (animals A and B) and two animals of the 3 days post-necrosis injection group (animals C and D) 1 month after vector injection. For each animal, both TA (ie R
,
L). For the other sample injected 5 days after necrosis (animal A; L), the copy number was less than 0.07 corresponding to the lower limit of detection of the Southern blot technique (not distinguishable from the background). No signal was detected for contralateral mature uninjured samples (animals A and B; R) and for muscle samples injected 3 days after necrosis (animals C and D; L).
Gene Therapy this time was associated with strong macrophagic infiltration of post-necrotic muscle tissue. This infiltrate of specialized phagocytic cells could have been responsible for the elimination of recombinant viral particles before their penetration into muscle cells. Five days after necrosis induction, muscle tissue was almost completely composed of young immature fibers, with little or no significant persistent inflammatory reaction. Even if dystrophic muscles show the coexistence of fiber necrosis, phagocytosis and concomitant regenerative attempts in the early stage of the disease, immature regenerative myofibers are particularly abundant in early stages of muscular dystrophies due to the different duration of this pathological phenomenons (ie few hours for myofiber necrosis, few hours for phagocytosis and several days for progressive growth and maturation of regenerative myofibers). 11, 12 In this context, the determination of the capability of the rAAV vectors to achieve efficient gene transfer in regenerating immature myofibers (numerous in 5 days post necrosis muscle) is of great concern.
The improved efficiency of rAAV-mediated gene transfer in regenerating muscle may have been due to one or more factors. First, changes in muscle connective tissue subsequent to necrosis and the ensuing inflammatory process may have facilitated the diffusion of vector solution between and within muscle fascicles. To test this hypothesis, gene transfer experiments involving intramuscular administration of vector solution were performed 3 h after pretreatment of rat TA by a mix of collagenase (50 g Collagenase H; Boehringer, Mannheim, Germany) and hyaluronidase (500 IU; Choay, Sanofi, France) in 500 l saline. Previous histologic studies of HES-stained sections had indicated that this pretreatment was associated with dissociation and reduction in the amount of interstitial connective muscle tissue, with no significant induction of myofiber lesions (data not shown). Contrary to previous reports in which hyaluronidase pretreatment was used alone, 10 no significant differences in the number of transduced myofibers (pretreated muscles: 340 ± 170 transduced fibers; non-pretreated muscle: 280 ± 120; Mann-Whitney test P = 0.32) or the distribution of transduced myofibers in muscle sections were observed in pretreated as compared with non-pretreated muscles 1 month after injection of viral solution. It was concluded that modification of interstitial connective tissue is probably not the most important factor in the improvement of gene transfer observed when rAAV injection was performed during muscle regeneration. Furthermore, regenerating muscle cells and newly formed myotubes may be surrounded by an immature basal lamina, which might not obstruct viral particles. To observe the changes occurring in basement membrane during muscle regeneration, histologic studies performed on periodic acid Schiffstained sections and immunodetection of laminin (2E8, 1:100; Hybridoma Bank, University of Iowa, USA) during regeneration showed that basement membrane was preserved from day 1 to 21 after notexin-induced injury. One day after necrosis induction, laminin expression was still detected around necrotic myofibers. Three days after injection, phagocytosis and satellite cell activation occurred inside the preserved basal lamina cylinders. The level of laminin expression then remained nearly constant during muscle regeneration, with no difference between the pattern for regenerating myofibers from day 5 to 21 after necrosis and that of uninjured myofibers (data not shown). Laminin labelling and basal lamina histological morphology were not affected by notexininduced injury or during subsequent muscle regeneration, which is consistent with previous reports on notexin-induced muscle injury. 13, 14 As assessed by a previous report, AAV transduction is not thus limited by basal lamina either in mature or regenerating muscle. 7 Even though the rAAV vectors used in the present study were replication-deficient, vector DNA amplification could have occurred in regenerating muscle if recombinant vector DNA integrated into myoblast genome, which proliferates actively during the early stages of the regenerative process. However, immunodetection by proliferating cell nuclear antigen (PCNA; PC10 clone, 1:100; Dako, France) showed that proliferation of satellite cells in muscle after notexin injection was completely finished 5 days after necrosis induction, whereas intense proliferative activity was observed from 1 to 3 days after myotoxic injury. Moreover, gene transfer in metabolically active regenerating myofibers could have been associated with faster vector DNA conversion into transcriptionally active intermediates than into mature quiescent myofibers. The existence of such differential kinetics in vector DNA processing could have been responsible for early apparent improvement of gene transfer efficiency in regenerating versus mature myofibers. However, medium-term studies showed comparable changes in transduction efficiency with time, whether vector injection was performed in regenerating or mature muscle. In both cases, a significant two-fold increase in the number of transduced myofibers was observed between 1 and 2 months after injection, and no further improvement occurred between 2 and 3 months ( Figure 5 ). Such equivalent chronological improvement in gene transfer efficiency is suggestive of comparable recombinant DNA processing kinetics in regenerating and mature fibers. Finally, muscle fiber growth may have led to increased transduction of transgene DNA because of associated enhancement of general protein metabolism. 15, 16 To test the hypothesis that increased gene transfer efficiency could be associated with an intense activity of protein synthesis, the effects of anabolic steroid treatment (5 mg/kg nandrolone laurate weekly) on gene transfer were evaluated. Systemic absorption of anabolic steroid was confirmed by body mass gain in steroid-treated animals (313 g ± 18), as compared with non-treated animals (248 g ± 12). TA muscle weight was also significantly different between the two groups of animals (ie 640 ± 50 mg in untreated animals versus 800 ± 90 mg in steroid-treated animals). However, steroid treatment induced increase in muscle mass by increasing myofiber size (myofiber hypertrophy) and not myofiber number which remained constant before and after treatment and was not significantly different between treated and untreated animals (8400 ± 500 myofibers in mature TA; 8750 ± 300 myofibers in regenerating TA). No significant improvement of gene transfer efficiency was found in steroid-treated animals as compared with untreated rats in uninjured (respectively 280 ± 110 transduced myofibers in steroidtreated rats versus 210 ± 125 in untreated rats) and regenerative muscle samples (respectively 720 ± 125 transduced myofibers in steroid-treated rats versus 760 ± 280 in untreated rats). Thus, an increase of cell metabolism and protein synthesis during regeneration was not involved in the enhancement of transgene expression. The presence of the primary AAV type 2 receptor, membrane-associated heparan sulfate proteoglycan (HSPG), 17 was investigated in mature and regenerating muscle tissue. In mature muscle, a slight HSPG level was found along the myofiber membrane ( Figure 6 ). Such expression of the primary attachment receptor for AAV is consistent with the ability of AAV type 2-based vectors to transfer genes efficiently in mature muscle tissue. Immunodetection of HSPG and slow myosin heavy chain isoform on serial sections of rat mature TA indicated that the level of HSPG expression and localization in rat muscle was independent of fiber contractile type ( Figure 6) . A recent study reported cytoplasmic overexpression of HSPG in mouse slow-twitch fibers, in association with better rAAV-mediated transduction efficiency in slowtwitch than fast-twitch fibers. 7 However, these authors detected no such HSPG overexpression in predominantly fast-twitch muscle of adult mice, which is consistent with our findings for fast-twitch TA of the young adult rat. Moreover, our experiments used an alternative, commercially available antibody reported to be highly specific for membrane-associated HSPG (F58-10EA, Seikagagu, Japan) and not cross-reactive with basal lamina-associated HSPG. 18 Our results indicate that membrane-localized expression of HSPG reached a peak in 5-day post- necrosis regenerating muscle (Figure 7) . At this stage, immunohistochemical detection of myosin heavy chain isoforms showed that regenerating myotubes coexpressed developmental (NCL-MHC-d, 1:20, Novocastra, France) and adult fast type II myosin isoform (fast pan II MHC: S5-15F4, 1:2,000; Biocytex, France). No adult slow type I myosin isoform-expressing myofibers were found until 7 to 10 days after notexin injury. These results imply that transduction efficiency in 5-day post-necrosis rat regenerating muscle was not dependent on the presence of slow myofibers. HSPG expression then decreased constantly after 5-days post-necrosis and during further progression of the regenerative process, showing an expression level 21 days after notexin injury similar to that found in uninjured mature muscle (Figure 7) . In all cases, HSPG expression was strictly located in myofiber sarcolemma, and no cytoplasmic expression was detected at any stage of the regenerative process. Our findings are consistent with previous studies reporting variable levels of membrane-associated HSPG expression during in vitro and in vivo muscle differentiation. 19, 20 This strong expression of the AAV receptor at its regular cellular location during the myotube growth period (ie around 5 days after necrosis induction) could be associated with facilitated interaction between viral particles injected into endomysial pericellular connective tissue and myofiber membrane. This might account for the better cellular entry of AAV-based vectors into regenerating than mature myofibers, and therefore the improvement of gene transfer efficiency during muscle regeneration.
Figure 5 Medium-term stability and improvement of transduction with time. Animals were killed 1, 2 or 3 months after viral injection. Quantification of transduction efficiency was performed by counting the number of myofibers on the whole muscle transverse section displaying ␤-gal enzymatic activity. Each dot represents one sample (five mature muscles and five muscles injected 5 days after necrosis were analyzed at 1,2 and 3 months after viral injection). The horizontal bar is the average number of X-gal-positive myofibers. Standard error is also plotted. Evaluation of transgene expression 2 months after rAAV injection showed a significant increase in the percentage of transduced myofibers with time. Two months after injection, a stable level of transgene expression was reached, and no further improvement was found between 2 and 3 months after rAAV injection. As observed 1 month after viral injection (230 ± 60 transduced myofibers in mature muscle versus 760 ± 230 transduced myofibers in 5-day post-necrosis regenerating muscle), a two-to three-fold increase of gene transfer efficiency was still observed in regenerating versus
Possible deleterious effects of the vector or transgene expression on transduced tissue were evaluated for safety reasons. Histopathological and immunohistochemical (detection of myosin isoforms) studies of all transduced muscle tissues were performed to evaluate the effects of rAAV gene transfer on mature muscle tissue or tissue in the process of muscle regeneration. The effects of rAAV Gene Therapy injection and transgene expression on the uninjured adult muscular phenotype were assessed 1, 2 and 3 months after gene transfer. No alteration of fiber type distribution and no modification of fiber type proportion were found between non-transduced and transduced muscle samples. The effect of rAAV injection and transgene expression on maturation and differentiation during regeneration was also evaluated by comparing non-transduced and transduced muscle samples. No evident alteration of the regenerative process was observed in transduced muscles, ie the percentage of post-necrotic myofibers displaying centrally localized nuclei was not significantly different between non-transduced (55.6% ± 3.5) and transduced (58.3% ± 3.5) muscles. Moreover, gene transfer did not alter the maturation process, as assessed by myofiber differentiation and growth, ie the mean diameter of the different fiber types was similar in non-transduced and transduced muscle samples (Table  1) .
However, T-lymphocyte infiltration was quite frequent (though minimal) around transduced myofibers at 1, 2 and 3 months, whether rAAV injection had been performed in mature or regenerating muscle (Figure 8 ). In the absence of detectable contaminants in our viral preparations (adenoviral or wild-type AAV), and considering the late onset of these inflammatory reactions, such inflammatory infiltrates were regarded as a limited immune reaction against foreign antigenic transgene product. Transient infiltrates following rAAV-mediated transduction of murine skeletal muscle have previously Values are means ± standard deviation: n = 5 animals for each group. All measurements were performed on an average of 150 myofibers per contractile type. Differences between transduced and non-transduced muscle were not significant (ANOVA; P = 0.71). been reported. 4, 6 These findings, which were restricted to some fiber segments expressing bacterial ␤-galactosidase enzyme, may reflect an immune response of cytotoxic T lymphocytes recognizing ␤-gal-derived peptides, presumably in association with major histocompatibility complex class I molecules at the surface of transduced fibers. In our experiments, such inflammatory reaction was not enhanced by previous experimentally induced regeneration.
Figure 8
Furthermore, increased transgene expression was observed with time ( Figure 5 ), which suggests that the inflammatory reaction generated no significant destruction of transduced cells or any subsequent inactivation of transgene expression.
In conclusion, our study indicates that rAAV type 2 was capable of efficient and even improved gene transfer in regenerating versus mature muscle tissue. Efficient gene transfer induced by an rAAV vector in regenerating, as well as mature muscle cells may be of particular interest for gene therapy of inherited muscular dystrophies in which numerous necrosis-regeneration cycles occur. Histopathological changes in dystrophic muscle show the coexistence, at least in the early stage of the disease, of myotubes and young and mature myofibers, which is responsible for the so-called heterogeneity of fiber size characteristic of the disease. Thus, a gene delivery system capable of producing efficient transduction in mature, as well as regenerating myofibers is required for effective long-term treatment of muscular dystrophies. 2 This capability of maturation-independent transduction of muscle cells with rAAV, as demonstrated in the present study, makes AAV-based vectors unique among viral gene delivery systems (ie adenovirus-, retrovirus-and herpes simplex virus 1-based vectors). Moreover, rAAVmediated gene transfer during muscle regeneration was not associated with impairment of the regenerative process. This absence of deleterious effects is of considerable importance in safety designs. Recent advances in recombinant vector technology have greatly enhanced the potential interest of AAV-based vectors for gene transfer in skeletal muscle. Recently constructed recombinant vectors derived from other serotypes than AAV type 2 (eg AAV type 1 and AAV type 5), which utilize different receptors for entering cells than AAV type 2, seem to show great promise for gene transfer in skeletal muscle. 21, 22 Further evaluation of these new serotypes in an experimental muscle necrosis-regeneration model, as performed in the present study for rAAV type 2, may be useful to evaluate their efficiency as a gene vector into pathologic muscles. Moreover, the large size of defective genes in most muscular dystrophies has, until recently, prevented the use of rAAV vectors for inherited muscle disease therapy, because of the 5 kb packaging limit of rAAV. However, as a result of advances in rAAV vector production technologies, it is now possible to overcome the size limitation of rAAV vectors and resolve the problem of packaging large genes into rAAV vectors. 23, 24 Altogether, these observations indicate that rAAV vector should be regarded as a promising candidate for gene transfer in pathologic muscle in the scope of gene therapy of acquired or inherited muscle disease, particularly muscular dystrophies.
